KCM
OCUL icon

Knoll Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Knoll Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-95,800
Closed -$814K – 39
2023
Q2 		$814K Hold
95,800
– – 0.99% 24
2023
Q1 		$505K Buy
+95,800
New +$455K 0.78% 24

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Knoll Capital Management's OCUL Position: Q2 2026 in Review

Knoll Capital Management increased its Ocular Therapeutix (OCUL) stake by 92% in Q2 2026, buying an estimated $4.99M and bringing the position to 1,150,400 shares worth $11.3M. The position accounts for 5.27% of the portfolio, ranked #5.

Knoll Capital Management first reported a position in OCUL in Q1 2023 and has held it in 14 quarters since. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Knoll Capital Management held 1,150,400 shares of Ocular Therapeutix worth $11.3M as of Q2 2026.
  • Knoll Capital Management bought 550,000 Ocular Therapeutix shares in Q2 2026, an estimated $4.99M.
  • Ocular Therapeutix made up 5.27% of Knoll Capital Management's portfolio in Q2 2026, its #5 holding.
  • Knoll Capital Management first reported a position in Ocular Therapeutix in Q1 2023 and has held it in 14 quarters since.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Knoll Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.